Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 2/3 1

Status

Recruiting 9Unknown 6Completed 6Active not recruiting 5Not yet recruiting 4Withdrawn 1Terminated 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 17Triple Negative Breast Neoplasms 5Neoplasms 2Stomach Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Lymphoma 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1Down Syndrome 1

Interventions

Carboplatin 25Paclitaxel 24pembrolizumab 22Cyclophosphamide 15Gemcitabine 10Capecitabine 10Doxorubicin 9Specimen Handling 8Nivolumab 8Taxes 7Magnetic Resonance Spectroscopy 7sacituzumab govitecan 6olaparib 6Cisplatin 6Albumin-Bound Paclitaxel 6eribulin 5durvalumab 5atezolizumab 5Radiotherapy 5Epirubicin 5130-nm albumin-bound paclitaxel 5capivasertib 4Docetaxel 4Biopsy 4niraparib 3Vinorelbine 3Radiation 3Blood Specimen Collection 3trastuzumab deruxtecan 2toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Triple Negative Breast Neoplasms × Epirubicin × Clear all
NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Lund University Hospital

Phase 3 Active not recruiting
325 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04296175 2025-03-26

CITRINE

Fudan University

Phase 3 Active not recruiting
808 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04418154 2024-05-21

NeoTENNIS

Fudan University

Phase 2 Active not recruiting
70 enrolled
Breast

Triple Negative Breast Neoplasms

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Fudan University

Phase 2/3 Active not recruiting
503 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02315196 2023-03-29

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Rutgers, The State University of New Jersey

Phase 2 Active not recruiting
62 enrolled 7 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡